The EDICT study, employing diabetes medications (GLP-1 receptor agonist, pioglitazone, metformin) that correct the basic underlying pathophysiologic defects present in type 2 diabetes, convincingly demonstrated that combination therapy produces a greater and more durable reduction in HbA1c than the treat-to-fail approach using diabetes medications (sulfonylureas, metformin, insulin) that do not correct the basic metabolic and cellular defects (insulin resistance and beta-cell dysfunction) present in type 2 diabetes patients
Biotin-thiamine-responsive basal ganglia disease
Updated meta-analysis on vitamin supplementation for chronic pruritus: expanding evidence beyond vitamin D
Subsequently, 60 studies were excluded due to the absence of alcohol-related outcomes, lack of GLP-1RA exposure, or unsuitable study design
However, because there are more than 60 KGDDs, there is a strong likelihood that changes in KG abundance also affect DNA-repair processes through other mechanisms